Riskpilot← Back to searchSign inGet full accessPharmaLex Denmark A/S
A/SActiveCVR 18652439Lyngby Hovedgade 10CBusiness and other management consultancy activities · NACE 7020Est. 199517 employees
Revenue 2025
DKK 17,2M
-34% vs 2024
EBITDA margin
-12.0%
-188% vs 2024
Equity ratio
15.1%
Financial strength
Net profit 2025
DKK -1,7M
-198% vs 2024
| Revenue | DKK 17,2M | -34% |
| EBITDA | DKK -2,1M | -188% |
| Net profit | DKK -1,7M | -198% |
| Total assets | DKK 18,3M | +46% |
| Equity | DKK 2,8M | -54% |
| Employees | 17 | — |
Legal name
PharmaLex Denmark A/S
CVR number
18652439
Legal form
Aktieselskab
NACE code
7020 · Business and other management consultancy activities
Founded
1. juli 1995
Share capital
DKK 550.000
Employees
17 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-09-30
Financial year
January – December
Signatory rights
Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af en direktør
Company purpose
Selskabets formål er konsulentvirksomhed, farmaceutisk virksomhed, handel, produktion samt landbrugsproduktion
Address
Lyngby Hovedgade 10C
Phone
+4574441936
Email
invoice@jacobsenadvice.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.855 | 12.678 | 15.365 | 17.575 | 22.356 | 14.540 | 13.392 | 17.037 | 21.537 | 22.718 | 29.957 | 20.503 | 26.015 | 17.235 |
| Staff expenses | -5.808 | -8.419 | -11.353 | -15.830 | -14.840 | -15.652 | -10.090 | -12.122 | -15.857 | -19.354 | -22.473 | -18.828 | -23.657 | -19.311 |
| EBITDA | 4.046 | 4.259 | 4.012 | 1.645 | 7.516 | -1.165 | 3.301 | 4.915 | 5.680 | 3.364 | 7.484 | 1.674 | 2.359 | -2.076 |
| Depreciation & amort. | -744 | -886 | -951 | -1.062 | -508 | -441 | -62 | -58 | -95 | -112 | -91 | -68 | -107 | -91 |
| EBIT | 3.302 | 3.373 | 3.062 | 584 | 7.008 | -1.606 | 3.239 | 4.857 | 5.585 | 3.252 | 7.393 | 1.606 | 2.251 | -2.167 |
| Net financials | -198 | -118 | -74 | -139 | -229 | -21 | -12 | -41 | -76 | 125 | -87 | -11 | -16 | -32 |
| Profit before tax | 3.104 | 3.255 | 2.987 | 444 | 6.780 | -1.627 | 3.228 | 4.816 | 5.509 | 3.377 | 7.305 | 1.595 | 2.235 | -2.199 |
| Tax | 782 | 787 | 749 | 123 | 1.461 | -0 | 353 | 1.121 | 1.243 | 743 | 1.525 | 351 | 489 | -487 |
| Net profit | 2.321 | 2.468 | 2.238 | 321 | 5.319 | -1.627 | 2.874 | 3.695 | 4.266 | 2.634 | 5.780 | 1.244 | 1.746 | -1.712 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 15.811 | 14.087 | 16.158 | 11.843 | 10.368 | 5.688 | 7.067 | 12.387 | 14.318 | 11.309 | 12.896 | 13.125 | 12.543 | 18.307 |
| Equity | 7.166 | 6.934 | 6.772 | 4.893 | 6.597 | 1.248 | 4.123 | 5.953 | 6.219 | 3.853 | 6.583 | 5.228 | 5.973 | 2.761 |
| Long-term debt | 5.810 | 4.245 | 3.982 | 3.717 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.000 |
| Short-term debt | 2.718 | 2.853 | 5.404 | 3.233 | 3.770 | 4.440 | 2.944 | 6.434 | 8.099 | 7.456 | 6.313 | 7.898 | 6.570 | 7.546 |
| Total debt | 8.528 | 7.098 | 9.386 | 6.950 | 3.770 | 4.440 | 2.944 | 6.434 | 8.099 | 7.456 | 6.313 | 7.898 | 6.570 | 15.546 |
EBITDA margin
-12.0%
This company
15.8%
Market median
-176% vs market
20122025
Equity ratio
15.1%
This company
38.2%
Market median
-60% vs market
20122025
Return on equity
-62.0%
This company
18.4%
Market median
-437% vs market
20122025
Net profit margin
-9.9%
This company
8.1%
Market median
-222% vs market
20122025
Asset turnover
0.94×
This company
1.12×
Market median
+16% vs market
20122025
Debt / equity
5.63×
This company
0.62×
Market median
-808% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via CVR / Virk · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-09-30
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PB Management | Management | 1995 | — | — |
EP Audit | Audit | 2002 | — | — |
LO Audit | Audit | 1995 | — | — |
TT Chief Executive Officer | Chief Executive Officer | 2017 | — | — |
HA Audit | Audit | 1995 | — | — |
ÅP Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 1995 | — | — | |
| Chairman | 2017 | — | — | |
| Board of Directors | 2006 | — | — | |
| Board of Directors | 2017 | — | — | |
| Chairman | 2016 | — | — | |
| Chairman | 2016 | — | — | |
EE | Board of Directors | 2024 | — | — |
| Board of Directors | 2006 | — | — | |
| Board of Directors | 2010 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2008 | — | — | |
| Board of Directors | 2016 | — | — | |
| Chairman | 2018 | — | — | |
| Board of Directors | 1995 | — | — | |
| Board of Directors | 2007 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 1995 | — | — | |
| Board of Directors | 1995 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Pharmalex Nordic ApS | Company | 100.0% | 100.0% | 2017 |
JAF INVEST ApS | Company | 100.0% | 100.0% | 2003 |
| Individual | 100.0% | 100.0% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Pharmalex Nordic ApS
PharmaLex Denmark A/S Board members of PharmaLex Denmark A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Preben Bang Henriksen | Management | 0 companies |
| Erik Peter Andersen | Audit | 0 companies |
| Leif Ove Rasmussen | Audit | 0 companies |
| Torben Thers Nørgaard | Chief Executive Officer | 0 companies |
| Harry Aamann | Audit | 0 companies |
| Åsa Pihlblad | Chief Executive Officer | 0 companies |
| Mogens Gaardboe Bertelsen | Chairman | 0 companies |
| Anette Langgaard Jacobsen | Chairman | 0 companies |
| Laurits Thorvald Larsen | Board of Directors | 0 companies |
| Solveig Blomvik | Board of Directors | 0 companies |
| Henrik Kagenow | Chairman | 0 companies |
| Raphael Troost | Chairman | 0 companies |
| Eva Edil | Board of Directors | 0 companies |
| Elsebeth Budolfsen | Board of Directors | 0 companies |
| Niels Bjerregaard | Board of Directors | 0 companies |
| Christopher Gauglitz | Chairman | 0 companies |
| Jakob Langgaard Wisnewski | Board of Directors | 0 companies |
| Caren Ingrid Martini | Board of Directors | 0 companies |
| Dr. Thomas Stefan Dobmeyer | Chairman | 0 companies |
| Lone Mai Henriksen | Board of Directors | 0 companies |
| Per Egebæk Have | Board of Directors | 0 companies |
| Laurent Maurice Robert Couston | Board of Directors | 0 companies |
| Finn Wisnewski | Board of Directors | 0 companies |
| Michael Clemmensen | Board of Directors | 0 companies |